Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2021 | 2 |
2024 | 1 |
Search Results
3 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial.
JAMA. 2021 Jan 5;325(1):50-58. doi: 10.1001/jama.2020.23370.
JAMA. 2021.
PMID: 33300950
Free PMC article.
Clinical Trial.
High-dose tamoxifen in high-hormone-receptor-expressing advanced breast cancer patients: a phase II pilot study.
Su Y, Zhang Y, Hua X, Huang J, Bi X, Xia W, Wang X, Huang Z, Song C, Zhong Y, Shi Y, Wang S; South China Breast Cancer Group (SCBCG); Fan W, Yuan Z.
Su Y, et al.
Ther Adv Med Oncol. 2021 Feb 26;13:1758835921993436. doi: 10.1177/1758835921993436. eCollection 2021.
Ther Adv Med Oncol. 2021.
PMID: 33737962
Free PMC article.
Item in Clipboard
Screening optimal candidates with operable, early-stage triple-negative breast cancer benefitting from capecitabine maintenance: A post-hoc analysis of the SYSUCC-001 study.
Duan F, Hua X, Bi X, Wang S, Shi Y, Xu F, Wang L, Huang J, Yuan Z, Huang Y; South China Breast Cancer Group (SCBCG).
Duan F, et al.
Breast. 2024 May 6;76:103740. doi: 10.1016/j.breast.2024.103740. Online ahead of print.
Breast. 2024.
PMID: 38733700
Free PMC article.
Item in Clipboard
Cite
Cite